Skip to main content
. 2014 Oct 14;9(10):e109428. doi: 10.1371/journal.pone.0109428

Figure 1. Xwnt5A-EGFP can compensate for the loss of endogenous Xwnt5A.

Figure 1

A) An anti-EGFP reactive protein of the expected size is produced by embryos injected with Xwnt5A-EGFP. 300 pg Xwnt5A-EGFP mRNA were injected into each blastomere of two-cell stage embryos. NOP lysates corresponding to one half embryo were separated on an 8% SDS PAGE, transferred onto nitrocellulose and incubated with an anti-EGFP and anti-tubulin antibody. B) 1.6 pmol Xwnt5A morpholino (5AMo) were injected together with the indicated amounts of Xwnt5A-EGFP mRNA in the two dorsal blastomeres of eight-cell stage embryos. At stage 10.25, dorsal marginal zones were explanted and analyzed for convergence and extension. C) Quantification of elongation and constriction phenotypes. Given is the portion of embryos with impaired constriction (left image) and impaired elongation (right image) of Xwnt5A morphants (Wnt5A_Mo) and morphants co-injected with the indicated amount of Xwnt5A-EGFP mRNA. N: number of independent experiments, n: number of analyzed explants. *: p<0.05, **: p<0.01, ***: p<0.001 according to Fisher's exact test.